NCT02945800 2026-04-02
Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
Clinical Trials
128 trialsNCT01525966 2026-03-30
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT00616967 2026-03-05
Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT03174275 2026-02-23
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT02530489 2026-02-17
Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02999477 2026-01-29
A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT04524702 2026-01-23
Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
Emory University
Phase 2 Completed
NCT04539808 2026-01-14
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT03910387 2025-12-16
Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer
Emory University
Phase 2 Completed
NCT03279237 2025-11-25
A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers
Massachusetts General Hospital
Phase 1 Completed
NCT02957968 2025-08-28
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
Virginia Commonwealth University
Phase 2 Active not recruiting
NCT03579771 2025-08-15
Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer
Emory University
Phase 2 Completed
NCT02769832 2025-07-29
Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer
University of Iowa
Phase 2 Completed
NCT01463072 2025-07-28
Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT02723331 2025-07-01
Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
University of Colorado, Denver
Phase 2 Completed
NCT02788981 2025-06-10
Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer
University of Chicago
Phase 2 Active not recruiting
NCT01730833 2025-06-03
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT01938833 2025-05-16
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Thomas Jefferson University
Phase 1/2 Terminated
NCT03107182 2025-05-06
OPTIMA-II
University of Chicago
Phase 2 Completed
NCT04581343 2025-05-04
PanCAN-SR1
Pancreatic Cancer Action Network
Phase 1 Completed
NCT01818063 2025-04-30
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
Thomas Jefferson University
Phase 2 Completed
NCT00583349 2025-02-17
Intravesicular Abraxane for Treatment-Refractory Bladder Cancer
Columbia University
Phase 1/2 Completed
NCT03655080 2025-02-04
Pulsed Abraxane and Radiotherapy for Improving and Maintaining Ambulation After Cancer-Related Cord Compression
Washington University School of Medicine
Phase 2 Terminated
NCT02752685 2025-01-29
Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer
NYU Langone Health
Phase 2 Active not recruiting
NCT03240016 2025-01-16
ABLE
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03535727 2024-12-31
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT02573493 2024-12-27
APA
Washington University School of Medicine
Phase 2 Completed
NCT03246074 2024-10-24
Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT02258659 2024-09-24
OPTIMA
University of Chicago
Phase 2 Completed
NCT03283761 2024-02-06
FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT02716038 2023-12-12
Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC
Columbia University
Phase 2 Completed
NCT02887248 2023-12-05
Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT03649321 2023-11-09
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Terminated
NCT02178436 2023-11-07
Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Completed
NCT03304210 2023-11-07
PIPAC-nabpac
University Hospital, Ghent
Phase 1 Completed
NCT03121352 2023-10-06
Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00499083 2023-09-29
Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
University of Nebraska
Phase 2 Completed
NCT02744898 2023-09-26
A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus
NYU Langone Health
Phase 2 Completed
NCT00934895 2023-09-18
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
Rutgers, The State University of New Jersey
Phase 1/2 Terminated
NCT02427841 2023-09-06
Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
OHSU Knight Cancer Institute
Phase 2 Completed
NCT01470417 2023-08-22
GAIN-1
University of Florida
Phase 2 Completed
NCT02710396 2023-07-24
Genetic Predictors of Benefit to Pembrolizumab
Columbia University
Phase 2 Terminated
NCT02382406 2023-05-23
Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC
Hoosier Cancer Research Network
Phase 1/2 Terminated
NCT02620865 2023-05-15
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Completed
NCT01147016 2023-04-27
Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT03112590 2023-04-19
Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT01036087 2023-03-30
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01565499 2023-03-30
Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer
Spanish Breast Cancer Research Group
Phase 2 Completed
NCT01446016 2023-01-23
CAT
The Methodist Hospital Research Institute
Phase 2 Completed
NCT02873598 2022-12-19
A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer
University of Colorado, Denver
Phase 1 Completed